Equities analysts expect Edwards Lifesciences Corp (NYSE:EW) to post $1.02 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Edwards Lifesciences’ earnings, with the lowest EPS estimate coming in at $0.99 and the highest estimate coming in at $1.08. Edwards Lifesciences reported earnings per share of $0.84 during the same quarter last year, which suggests a positive year-over-year growth rate of 21.4%. The company is scheduled to report its next quarterly earnings report on Tuesday, October 23rd.

According to Zacks, analysts expect that Edwards Lifesciences will report full year earnings of $4.67 per share for the current year, with EPS estimates ranging from $4.60 to $4.71. For the next year, analysts anticipate that the company will post earnings of $5.24 per share, with EPS estimates ranging from $4.91 to $5.50. Zacks’ EPS calculations are an average based on a survey of research firms that cover Edwards Lifesciences.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company had revenue of $972.00 million during the quarter, compared to analysts’ expectations of $968.32 million. During the same period in the previous year, the company earned $1.08 EPS. The business’s quarterly revenue was up 10.0% compared to the same quarter last year.

EW has been the subject of several research reports. BMO Capital Markets boosted their price objective on shares of Edwards Lifesciences to $162.00 and gave the company an “outperform” rating in a research note on Tuesday, July 10th. ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Tuesday, June 12th. Royal Bank of Canada boosted their price objective on shares of Edwards Lifesciences to $145.00 and gave the company an “outperform” rating in a research note on Wednesday, May 23rd. Northland Securities reissued a “hold” rating and set a $120.00 price objective on shares of Edwards Lifesciences in a research note on Friday, July 27th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $133.00 to $150.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $152.45.

In other Edwards Lifesciences news, VP Huimin Wang sold 3,800 shares of the business’s stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $146.60, for a total value of $557,080.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of the business’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $144.16, for a total transaction of $792,880.00. Following the completion of the transaction, the vice president now owns 25,490 shares in the company, valued at approximately $3,674,638.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 183,811 shares of company stock valued at $26,346,476. 1.84% of the stock is owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. Optimum Investment Advisors acquired a new position in Edwards Lifesciences in the 1st quarter worth $110,000. Private Capital Group LLC acquired a new position in Edwards Lifesciences in the 2nd quarter worth $112,000. Centaurus Financial Inc. acquired a new position in Edwards Lifesciences in the 2nd quarter worth $114,000. IHT Wealth Management LLC lifted its holdings in Edwards Lifesciences by 84.6% in the 1st quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock worth $126,000 after buying an additional 427 shares in the last quarter. Finally, Signet Financial Management LLC acquired a new position in Edwards Lifesciences in the 2nd quarter worth $136,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Shares of NYSE EW traded down $0.34 during trading on Tuesday, hitting $145.95. 842,300 shares of the company traded hands, compared to its average volume of 1,285,302. Edwards Lifesciences has a 1 year low of $100.20 and a 1 year high of $156.87. The stock has a market capitalization of $30.99 billion, a PE ratio of 38.57, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.47, a current ratio of 1.86 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Edwards Lifesciences (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.